Aptevo Therapeutics' stock rose 12% due to positive Phase 1 trial results for cancer drug ALG.APV-527 with partners Alligator Bioscience.
Aptevo Therapeutics stock surged 12% on Thursday as the company reported positive early trial results for cancer drug ALG.APV-527 in a Phase 1 trial with partners Alligator Bioscience. The drug is being tested to treat solid tumors likely to express tumor antigen 5T4. The trial, now over 50% enrolled, has shown the drug to be well-tolerated so far, with biomarker analyses confirming its biological activity.
March 07, 2024
3 Articles